𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients

✍ Scribed by Sameh Adel Fayek; Wana Mantipisitkul; Flavia Rasetto; Raghava Munivenkatappa; Rolf N. Barth; Benjamin Philosophe

Book ID
111221111
Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
258 KB
Volume
12
Category
Article
ISSN
1365-182X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Valganciclovir for cytomegalovirus proph
Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients
✍ Jeong M. Park; Kathleen D. Lake; Robert J. Fontana πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 48 KB

We thank Jain et al. for their interest and correspondence regarding our recently published study. 1 The authors note that the incidence of cytomegalovirus (CMV) disease in our retrospective study was much lower than that reported by others. As acknowledged in our article, we did not use routine sur

Question of using valganciclovir for cyt
Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post–liver transplant recipients
✍ Ashok Jain; Ravi Mohanka; Mark Orloff; Peter Abt; Charlotte Ryan; Adel Bozorgzad πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 46 KB

We read the article by Park et al. with great interest. 1 The authors retrospectively studied the efficacy of low-dose oral valganciclovir (n Ο­ 49) compared with the standard dose of ganciclovir (n Ο­ 60) for the prevention of cytomegalovirus (CMV) disease in adult liver transplant recipients. The au